About Dr. Zheng Jie
Dr. Zheng Jie (郑捷) is one of China's most distinguished dermatologists and a nationally recognized authority on psoriasis, autoimmune skin diseases, and inflammatory dermatology. She serves as Director of the Department of Dermatology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and holds the title of Chief Physician and Professor.
Over a career spanning more than three decades, Dr. Zheng has established Ruijin Hospital's Dermatology Department as one of the premier skin disease centers in China. She is particularly renowned for her expertise in psoriasis and autoimmune bullous diseases — areas where her contributions have shaped national clinical guidelines and influenced dermatology practice across Asia. Her research on the immunopathogenesis of psoriasis in Chinese patients has been widely cited internationally and has directly informed the development of biologic therapies for Asian populations.
International patients with chronic inflammatory skin diseases, autoimmune dermatoses, or complex skin conditions consistently identify Dr. Zheng as one of China's top dermatologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Past President, Chinese Society of Dermatology
- Chair, Psoriasis Committee, Chinese Society of Dermatology
- Editorial Board Member: Journal of Investigative Dermatology, British Journal of Dermatology, Journal of the European Academy of Dermatology and Venereology (JEADV)
- Member, International Psoriasis Council (IPC)
- Member, European Academy of Dermatology and Venereology (EADV)
- Principal Investigator, multiple national and international multicenter clinical trials in psoriasis and autoimmune skin disease
Specialties and Clinical Expertise
Dr. Zheng's clinical practice covers the full breadth of dermatology, with particular depth in immune-mediated and inflammatory skin diseases. Her approach integrates the latest molecular diagnostics with individualized, evidence-based treatment strategies.
- Psoriasis — plaque, guttate, pustular, erythrodermic, and nail psoriasis; biologic therapy (IL-17 inhibitors: secukinumab, ixekizumab; IL-23 inhibitors: guselkumab, risankizumab; TNF inhibitors; IL-12/23 inhibitor: ustekinumab) and small molecule therapy (apremilast, deucravacitinib); treat-to-target protocols and long-term remission maintenance
- Autoimmune Bullous Diseases — pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita; rituximab, IVIG, and immunosuppressive protocols
- Atopic Dermatitis (Eczema) — moderate-to-severe disease; dupilumab, tralokinumab, and JAK inhibitor therapy (upadacitinib, abrocitinib); proactive maintenance strategies
- Lupus Erythematosus (Cutaneous) — discoid lupus, subacute cutaneous lupus, and lupus-specific skin manifestations; coordinated care with rheumatology
- Dermatomyositis — skin manifestations, interstitial lung disease surveillance, and immunosuppressive management
- Urticaria and Angioedema — chronic spontaneous urticaria; omalizumab therapy and allergen workup
- Skin Oncology — melanoma, basal cell carcinoma, squamous cell carcinoma, and cutaneous lymphoma; Mohs micrographic surgery referral and immunotherapy coordination
- Vitiligo — JAK inhibitor therapy (ruxolitinib cream), NB-UVB phototherapy, and combination approaches for repigmentation
- Alopecia Areata — JAK inhibitor therapy (baricitinib, ritlecitinib) and immunotherapy protocols
Academic and Research Contributions
Dr. Zheng Jie has published over 260 peer-reviewed papers in leading international dermatology journals, with a particular focus on the immunopathogenesis of psoriasis and the clinical pharmacology of biologic therapies in Chinese patients. Her landmark research on the genetic and immunological basis of psoriasis in Han Chinese populations has been cited extensively in international guidelines and has contributed to the understanding of ethnic differences in psoriasis biology and treatment response.
She has led or co-led numerous pivotal clinical trials that brought biologic therapies — including secukinumab, ixekizumab, guselkumab, risankizumab, dupilumab, and deucravacitinib — to Chinese patients, often serving as the China Principal Investigator for global Phase III registration trials. Her work has been instrumental in establishing China as a major contributor to global dermatology clinical research.
Dr. Zheng is a past President of the Chinese Society of Dermatology and has chaired the Psoriasis Committee for multiple terms, leading the development of China's national psoriasis treatment guidelines. She is a regular invited speaker at the European Academy of Dermatology and Venereology (EADV), the International Investigative Dermatology (IID) congress, and the World Congress of Dermatology (WCD).
Approach to Patient Care
Dr. Zheng is known for her thorough, evidence-driven approach to complex dermatological cases. She leads a multidisciplinary team that brings together dermatologists, rheumatologists, immunologists, and oncologists to develop comprehensive management plans for patients with systemic autoimmune skin diseases or skin manifestations of internal disease.
For international patients — many of whom arrive with chronic skin conditions that have been inadequately managed or misdiagnosed overseas — Dr. Zheng takes particular care to review all available clinical history, biopsy results, and prior treatment records before forming an independent clinical opinion. Her familiarity with international treatment standards (EADV, AAD, BAD guidelines) makes her an ideal consultant for patients transitioning from Western healthcare systems or seeking access to therapies not yet available in their home country.
Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital is one of China's most prestigious academic medical centers, consistently ranked among the top hospitals nationally. The Department of Dermatology at Ruijin is a National Key Clinical Specialty and one of the highest-volume skin disease centers in China. The department operates:
- A dedicated Psoriasis Biologic Therapy Clinic administering the full range of approved IL-17, IL-23, TNF, and IL-4/13 inhibitors
- An Autoimmune Bullous Disease Unit with inpatient capability for severe pemphigus and bullous pemphigoid
- A Phototherapy Center with NB-UVB, PUVA, and targeted phototherapy for psoriasis, vitiligo, and atopic dermatitis
- A Dermatopathology Laboratory with direct immunofluorescence capability for autoimmune bullous disease diagnosis
- A Clinical Trials Unit running multiple Phase II-III studies in psoriasis, atopic dermatitis, and alopecia areata
Why International Patients Choose Dr. Zheng Jie
- China's leading psoriasis specialist — national guideline author, past President of the Chinese Society of Dermatology, and IPC member
- Full biologic therapy access — all approved IL-17, IL-23, IL-4/13 inhibitors, JAK inhibitors, and novel agents
- Autoimmune bullous disease expertise — one of China's foremost authorities on pemphigus and bullous pemphigoid
- Clinical trial access — patients may be eligible for cutting-edge therapies not yet commercially available
- EADV/AAD-aligned practice — familiar with international guidelines, ideal for patients from Western healthcare systems
- Second opinion authority — regularly reviews complex overseas cases for international patients
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Ruijin Hospital, 197 Ruijin Er Road, Huangpu District, Shanghai
- Appointment Lead Time: 2–3 weeks for new patients; urgent cases may be expedited through CMCS
- Consultation Format: In-person consultation; remote pre-consultation record review available through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Medical Records: CMCS provides full translation of overseas medical records, biopsy reports, and prior treatment history into Chinese prior to consultation
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking consultation or treatment with Dr. Zheng Jie at Ruijin Hospital. Our services include:
- Priority appointment booking and scheduling coordination
- Medical record and biopsy report translation (English ↔ Chinese)
- Remote pre-consultation record review facilitation
- On-site interpretation during consultations and procedures
- Accommodation coordination near Ruijin Hospital
- Insurance liaison and billing support
- Post-treatment follow-up coordination with your home country dermatologist
- Clinical trial eligibility assessment for psoriasis, atopic dermatitis, and alopecia areata studies
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
댓글 0개